Hodgkin lymphoma
Drug research and approvals for hodgkin lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 1,016 studies of hodgkin lymphoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 24 drug trials for it since 2013, FDA has 9 approved and 3 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 1,016
- Trials authorized in Canada: 24
- FDA orphan approvals: 9
- EU medicines: 1
- First in Human Study of a Dual Targeting CD20 and CD19 CAR T Cell Treatment for Patients With B Cell Blood Cancers That…NCT07948733 · Phase 1 · Cellogen Therapeutics Pvt. Ltd. · starts Oct 26, 2026
- Simulation-Free Single-Fraction Radiation Therapy for Indolent LymphomaNCT07945470 · Not applicable · University Health Network, Toronto · starts Oct 9, 2026
- Multimodal Ultrasound for Lymphoma Classification and Treatment Response PredictionNCT07941063 · Not reported · Chinese PLA General Hospital · starts Jan 1, 2026
- Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment…NCT07934537 · Phase 4 · Shanghai Tongji Hospital, Tongji University School of Medicine · starts Oct 30, 2025
- Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute…NCT07936266 · Phase 1 · Sunil G. Iyer · starts Mar 31, 2027
- CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaNCT07927816 · Phase 1 · Liping Dou · starts Sep 1, 2026
- GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic LeukemiaNCT07910708 · Phase 1 · Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital · starts Aug 4, 2026
- Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and…NCT07908888 · Phase 4 · The First Hospital of Jilin University · starts Oct 15, 2026
- Toxicity of Intensive First-Line Treatment for Adult Burkitt Lymphoma: A Retrospective Observational StudyNCT07895927 · Not reported · University Hospital, Strasbourg, France · starts Feb 11, 2026
How its trials ended
818 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 242 whose ending is known, 48% met their primary endpoint, 3% missed it and 50% stopped early.
- Completed, result not reported33140%
- Ongoing17822%
- Met its primary endpoint11514%
- Status unknown678%
- Stopped: other or unclear547%
- Stopped: enrollment or feasibility354%
- Stopped: sponsor or business decision182%
- Missed its primary endpoint71%
- Stopped: funding71%
- Stopped: lack of efficacy51%
- Stopped: safety1<1%
| May 14, 2024 | Norm: nodular lymphocyte-predominant Hodgkin lymphoma patients treated in a randomized phase 2 trial with either rituximab or mosunetuzumabMosunetuzumab (nsc 833090) | Dr. Anca Prica | Ongoing |
| Jul 20, 2023 | A randomized phase 3 interim response adapted trial comparing standard therapy with immuno-oncology therapy for children and adults with newly diagnosed stage…Nivolumab / Brentuximab vedotin / Etoposide phosphate | Childrens Oncology Group | Ongoing |
| May 25, 2023 | A randomised phase III trial with a pet response adapted design comparing abvd +/- isrt with A2VD +/- isrt in patients with previously untreated stage ia/iia…Adcetris | Canadian Cancer Trials Group, Cancer Research Institute, Queen's University | Ongoing |
| Apr 5, 2023 | A phase 3 randomized clinical study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) versus physician's choice chemotherapy in…MK-4280A (favezelimab (MK-4280)-pembrolizumab (MK-3475)) | Merck & Co. (MSD) | Ongoing |
| Mar 3, 2022 | A phase 1, open-label, dose-escalation and dose-expansion study of NL-201 in patients with B-cell lymphoma, Hodgkin lymphoma, or multiple myelomaNL-201 | Neoleukin Therapeutics Inc. | Pending |
| Jan 21, 2022 | A randomized phase II trial of pembrolizumab and brentuximab vedotin versus gdp followed by high dose chemotherapy and autologous stem cell transplantation for…Adcetris / Keytruda | Canadian Cancer Trials Group, Cancer Research Institute, Queen's University | Ongoing |
| Jan 10, 2022 | "a phase I/II open-label, multi-center study to assess safety, tolerability, pharmacokinetics and preliminary efficacy of AZD7789, an ANTI-PD-1 and ANTI-TIM-3…AZD7789 | AstraZeneca Pharmaceuticals | Closed |
| Aug 12, 2021 | Phase 2 study of pembrolizumab and chemotherapy in patients with newly diagnosed classical Hodgkin lymphoma (keynote-C11)Pembrolizumab (MK-3475) | Merck & Co. (MSD) | Ongoing |
| May 19, 2021 | A phase 2 study of pembrolizumab (MK-3475) every 6 weeks (Q6W) in participants with relapsed or refractory classical Hodgkin's lymphoma (RRCHL) or relapsed or…Keytruda | Merck & Co. (MSD) | Ongoing |
| Dec 14, 2020 | Multiple part clinical trial of brentuximab vedotin in classical Hodgkin lymphoma subjectsAdcetris (brentuximab vedotin) | Pfizer | Pending |
| Mar 20, 2026 | OpdivoIn combination with doxorubicin, vinblastine, and dacarbazine (AVD), for the treatment of adult and pediatric patients 12 years and older… | Bristol-Myers Squibb Company | Approved |
| Nov 10, 2022 | AdcetrisTreatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL) in combination with… | Seagen Inc. | Approved |
| Oct 14, 2020 | KeytrudaTreatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL); and treatment of pediatric patients with… | MSD International Business GmbH | Approved |
| Mar 20, 2018 | AdcetrisADCETRIS® is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in… | Seagen Inc. | Approved |
| Apr 25, 2017 | OpdivoTreatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell… | Bristol-Myers Squibb Company | Approved |
| Mar 14, 2017 | KeytrudaTreatment for adult and pediatric patients with refractory classical Hodgkin Lymphoma (cHL), or who have relapsed after 3 or more prior… | MSD International Business GmbH | Approved |
| May 17, 2016 | OpdivoTreatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell… | Bristol-Myers Squibb Company | Approved |
| Aug 17, 2015 | AdcetrisTreatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell… | Seagen Inc. | Approved |
| Aug 19, 2011 | AdcetrisThe treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two… | Seagen Inc. | Approved |
| Apr 29, 2015 | (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-met…Treatment of Hodgkin lymphoma | Incyte Corporation | Designated |
| Aug 20, 2009 | Recombinant antibody construct against human CD30 and CD16ATreatment of Hodgkin lymphoma | Affimed GmbH | Designated |
| Dec 2, 2008 | Anti-CD30 Fc engineered humanized monoclonal antibodyTreatment of Hodgkin lymphoma | Xencor, Inc. | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Oct 25, 2012 | AdcetrisBrentuximab vedotin | Takeda Pharma A/S | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA